Shots:
- Eolas Therapeutics has secured full development rights from AstraZeneca for AZD4041 to treat opioid use disorder (OUD) and other substance use disorders; terms remain confidential
- As per the agreement, Eolas will take full responsibility for AZD4041 under the existing IND and advance it to P-II trials with NIDA UG3 support, focusing on a patient-centered development across multiple indications
- AZD4041, a selective orexin-1 receptor antagonist co-developed by Eolas and AstraZeneca with NIDA support, targets neural circuits involved in addiction. Preclinical and early clinical data suggest its potential as a first-in-class, non-opioid treatment for opioid, stimulant, and alcohol use disorders
Ref: Businesswire | Image: | Press Release
Related News:- AstraZeneca Reports the EC’s Approval for Perioperative Imfinzi to Treat Muscle-Invasive Bladder Cancer (MIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
